Abstract:Background: Previous studies have suggested that the gut microbiota (GM) is closely associated with the development of autoimmune cholestatic liver disease (ACLD), but limitations, such as the presence of confounding factors, have resulted in a causal relationship between the gut microbiota and autoimmune cholestatic liver disease that remains uncertain. Thus, we used two-sample Mendelian randomization as a research method to explore the causal relationship between the two. Methods: Pooled statistics of gut microbiota from a meta-analysis of genome-wide association studies conducted by the MiBioGen consortium were used as an instrumental variable for exposure factors. The Pooled statistics for primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) were obtained from the R9 version of the FinnGen database (https://r9.finngen.fi/). Inverse-variance Weighted (IVW), cML-MA, MR-Egger regression, Weighted median (WME), Weighted mode (WM), and Simple mode (SM) were used to detect the association between intestinal flora and the causal relationship between intestinal flora and ACLD, in which IVW method was dominant, was assessed based on the effect indicator dominance ratio (odds ratio, OR) and 95% confidence interval (CI). Sensitivity analysis, heterogeneity test, gene pleiotropy test, MR pleiotropy residual sum and outlier test (MR-PRESSO) were combined to verify the stability and reliability of the results. Reverse Mendelian randomization analysis was performed on gut microbiota and found to be causally associated with ACLD. Results: The IVW results showed that the relative abundance of the genus Clostridium innocuum group, genus Butyricicoccus , and genus Erysipelatoclostridium was negatively correlated with the risk of PBC, that is, increased abundance reduced the risk of PBC and was a protective, and the relative abundance of the genus Eubacterium hallii was positively correlated with the risk of PSC, which is a risk factor for PSC. Family Clostridiaceae1 and family Lachnospiraceae were negatively correlated with the risk of PSC, which is a protective factor for PSC. Conclusion: This study found a causal relationship between gut microbiota and ACLD. This may provide valuable insights into gut microbiota-mediated pathogenesis of ACLD. It is necessary to conduct a large-sample randomized controlled trial (RCT) at a later stage to validate the associated role of the relevant gut microbiota in the risk of ACLD development and to explore the associated mechanisms.

Causal relationships between the gut microbiota, inflammatory cytokines, and alcoholic liver disease: a Mendelian randomization analysis

The causal relationship between gut microbiota and end-stage liver disease: a bidirectional Mendelian randomization analysis

Exploring the impact of inflammatory cytokines on alcoholic liver disease: a Mendelian randomization study with bioinformatics insights into potential biological mechanisms

Investigating causal associations among gut microbiota, metabolites, and liver diseases: a Mendelian randomization study

Associations Between Gut Microbiota and Alcohol Abuse: A Mendelian Randomisation and Bioinformatics Study

The Causality Between Gut Microbiome and Liver Cirrhosis: a Bi-Directional Two-Sample Mendelian Randomization Analysis

Metabolites mediate the causal associations between gut microbiota and NAFLD: a Mendelian randomization study

Causal Relationship Between Gut Microbiota and Liver Cirrhosis: 16S rRNA Sequencing and Mendelian Randomization Analyses

Alcohol or Gut Microbiota: Who Is the Guilty?

Metabolites Mediate the Causal Associations Between Gut Microbiota and NAFLD：a Mendelian Randomization Study

Causal associations of genetically predicted gut microbiota and blood metabolites with inflammatory states and risk of infections: a Mendelian randomization analysis

Association between gut microbiota and autoimmune cholestatic liver disease, a Mendelian randomization study

Dissecting the association between gut microbiota and liver cancer in European and East Asian populations using Mendelian randomization analysis

Impact of gut microbiota on nonalcoholic fatty liver disease: insights from a leave-one-out cross-validation study

Genetically predicted immune cells mediate the association between gut microbiota and autoimmune liver diseases

Roles of Human Gut Microbiota in Liver Cirrhosis Risk: A Two-Sample Mendelian Randomization Study.

Association between the gut microbiota, inflammatory factors, and colorectal cancer: evidence from Mendelian randomization analysis

Roles of Gut Microbiota in Alcoholic Liver Disease

Association between the gut microbiota and nonalcoholic fatty liver disease: A two-sample Mendelian randomization study

Assessment of causal associations among gut microbiota, metabolites, and celiac disease: a bidirectional Mendelian randomization study

Causal impact of gut microbiota on five liver diseases: insights from mendelian randomization and single-cell RNA sequencing